ArticleFrontiers in microbiology2023
Antimicrobial activity, membrane interaction and structural features of short arginine-rich antimicrobial peptides.
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Recent Progress in Antimicrobial Peptides (AMPs) Towards Enhanced Selectivity and Reduced Cytotoxicity by Molecular Engineering.Biotechnology and bioengineering · 2026Review
- Comparative Biological and Functional Profiling of Single-Position Cysteine Substitutions in the HNP-1-Derived Peptide Pep-H AgainstAntibiotics (Basel, Switzerland) · 2026Article
- Functional Peptides: Comparing Synthetic and Sequence-Engineered Antibiofilm Pharmaceutics.Pharmaceutics · 2026Review
- Investigation of the Antibacterial Effectiveness of Hybrid Recombinant Bacteriocins Circular Enterocin and Pyocin L1 Derived from Pseudomonas aeruginosa and Enterococcus faecalis.Biochemical genetics · 2026Article
- From Polyphenols to β-Lactamases: Multitarget Strategies to Defeat Severe Resistance.International journal of molecular sciences · 2026Review
- Selective Interaction of the Antimicrobial Peptide RKW with Bacterial Lipid Bilayers: A Biophysical Approach.ACS omega · 2026Article
- Potential Molecular Targets of the Broad-Range Antimicrobial Peptide Tyrothricin in the Apicomplexan ParasiteBiomedicines · 2026Article
- Repurposing an antimicrobial arginine-rich decapeptide as a novel anticancer agent: Evidence fromIranian journal of basic medical sciences · 2026Article
- Antimicrobial peptides in the era of resistance: integrating AI-driven design, host-microbe interactions, and nanotechnological delivery.Frontiers in microbiology · 2026Review
- Production and Characterisation of Mobilisin, a Broad-Spectrum Antimicrobial Peptide from Bacillus mobilis.Applied biochemistry and biotechnology · 2026Article
- Discovery of a Potent Antimicrobial Peptide Through Rational Design: A New Frontier in Pathogen Control.Biomolecules · 2025Article
- Unlocking the power of membrane biophysics: enhancing the study of antimicrobial peptides activity and selectivity.Biophysical reviews · 2025Review
- Engineering of antimicrobial peptide Brevinin-1pl: arginine, lysine, and histidine substitutions enhance antimicrobial-anticancer efficacy with reduced cytotoxicity.Frontiers in chemistry · 2025Article
- Senegalin-2: A Novel Hexadecapeptide fromBiomolecules · 2024Article
- Novel Tree Shrew-Derived Antimicrobial Peptide with Broad-Spectrum Antibacterial Activity.ACS omega · 2024Article
- Anti-Herpetic Activity of Killer Peptide (KP): An In Vitro Study.International journal of molecular sciences · 2024Article
- A Reliable Multifaceted Solution against Foodborne Viral Infections: The Case of RiLK1 Decapeptide.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial activity of many AMPs can be improved by lysine-to-arginine substitution due to a more favourable interaction of arginine guanidinium moiety with bacterial membranes. In a previous work, the structural and functional characterization of an amphipathic antimicrobial peptide named RiLK1, including lysine and arginine as the positively charged amino acids in its sequence, was reported. Specifically, RiLK1 retained its β-sheet structure under a wide range of environmental conditions (temperature, pH, and ionic strength), and exhibited bactericidal activity against Gram-positive and Gram-negative bacteria and fungal pathogens with no evidence of toxicity on mammalian cells. To further elucidate the influence of a lysine-to-arginine replacement on RiLK1 conformational properties, antimicrobial activity and peptide-liposome interaction, a new RiLK1-derivative, named RiLK3, in which the lysine is replaced with an arginine residue, was projected and characterised in comparison with its parental compound. The results evidenced that lysine-to-arginine mutation not only did not assure an improvement in the antimicrobial potency of RiLK1 in terms of bactericidal, virucidal and fungicidal activities, but rather it was completely abolished against the hepatitis A virus. Therefore, RiLK1 exhibited a wide range of antimicrobial activity like other cationic peptides, although the exact mechanisms of action are not completely understood. Moreover, tryptophan fluorescence measurements confirmed that RiLK3 bound to negatively charged lipid vesicles with an affinity lower than that of RiLK1, although no substantial differences from the structural and self-assembled point of view were evidenced. Therefore, our findings imply that antimicrobial efficacy and selectivity are affected by several complex and interrelated factors related to substitution of lysine with arginine, such as their relative proportion and position. In this context, this study could provide a better rationalisation for the optimization of antimicrobial peptide sequences, paving the way for the development of novel AMPs with broad applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.